An analysis of 29 chemotherapeutic trials in 18 male patients with advanced breast cancer disclosed an overall response rate of 44%. Most of these chemotherapeutic trials consisted of single-agent regimens, namely, fluorouracil, methotrexate, thiotepa, cyclophosphamide, and melphalan. Our data suggest ...
Chemotherapyforbreast canceruses medicine to killcancercells. You'll likely get the treatment as an infusion through a vein or as a pill. In most cancer centers, a large majority of patients will get an infusion through a central port in the chest wall, instead of in their arm. Your doc...
advancedCAFweeklyIn a prospective phase II study, 102 women with advanced breast cancer were treated with low doses of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) at weekly intervals by intravenous injection. Seventy-five patients were evaluable for treatment response and the overall response...
(doxorubicin) and Cytoxan (cyclophosphamide)—known as “AC chemotherapy”—and had fewer side effects. The regimens were tested in patients with stage 1 to 3 breast cancer who had undergone surgery to remove their primary tumor. Effectiveness was measured by disease-free survival an average of ...
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm Cancer, 74 (1994), pp. 1283-1288 Google Scholar 14. D.A. Cameron, E.D. Anderson, P. Levack, et al. Primary systemic therapy for operable breast cancer...
Neoadjuvant therapy is used to eradicate cancer from the lymph nodes, and patients with breast cancer that has spread to the regional lymph nodes could be eligible for neoadjuvant chemotherapy. According to Eleftherios “Terry” Mamounas, MD, MPH, there is no established standa...
aIdentification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. 预断基因的证明为周期性风险预言在三倍消极乳腺癌患者在台湾。[translate] aAdvantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of pro...
I wish to clarify several points attributed to me in the recent MEDICAL NEWS article (1980;244:1079) on the National Cancer Institute Consensus Conference on Adjuvant Chemotherapy of Breast Cancer.1Regarding the use of adjuvant chemotherapy for node-negative (stage I) cases, I reported on the ...
* High-dose chemotherapy does not benefit all patients with high-risk breast cancer and future trials should focus on identifying subsets of patients who benefit from such therapy based on their tumor characteristics like HER2 status. * Novel strategies of delivering high-dose chemotherapy like rapid...
Data on chemotherapy for elderly patients with metastatic breast carcinoma (MBC) are limited. We performed a 7-year retrospective analysis of MBC patients at our institution receiving first-line chemotherapy aged ≥75 years. Of 117 patients, 103 received monotherapy (67 capecitabine, 29 vinorelbine,...